Efficacy News and Research

RSS

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Erlotinib can be intercalated with the anti-tubule agent eribulin mesylate for patients with advanced non-small-cell lung cancer but it is unlikely to increase treatment efficacy in those without epidermal growth factor receptor activating mutations, research suggests.

25 Jun 2014

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its Phase 2b trial for once-daily, quadruple-action RoclatanTM, a combination of Aerie's triple-action RhopressaTM with latanoprost, a prostaglandin analogue (PGA).

25 Jun 2014

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Henry Ford Health System has launched a clinical trial to investigate a new drug for the treatment of tinnitus, a chronic ringing of the head or ears that affects more than 600 million people worldwide.

25 Jun 2014

Mode of cancer cell recognition opens up new possibilities for leukaemia immunotherapy

Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukaemia cells that are detected by a unique group of immune cells. By recognising the lipids, the immune cells stimulate an immune response to destroy the leukaemia cells and suppress their growth.

25 Jun 2014

Small antioxidant molecules suppress colon cancer associated with colitis

Researchers from Case Western Reserve and Dartmouth universities have shown that a class of small antioxidant molecules carries enormous promise for supressing colon cancer associated with colitis.

25 Jun 2014

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

25 Jun 2014

New study shows that bariatric patients face lower cancer risks

A new study published in the journal Obesity Surgery indicates that bariatric patients benefit from a significantly decreased risk of cancer compared to other obese patients.

25 Jun 2014

Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.

24 Jun 2014

SLU researchers discover pain pathway and potential way to block it

In a recently published study in the Journal of Biological Chemistry, Saint Louis University professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D. describes two discoveries: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it.

24 Jun 2014

New invention provides simple, highly effective way for patients to self-treat keloid scars

Scars - in particular keloid scars that result from overgrowth of skin tissue after injuries or surgeries - are unsightly and can even lead to disfigurement and psychological problems of affected patients. Individuals with darker pigmentation - in particular people with African, Hispanic or South-Asian genetic background - are more likely to develop this skin tissue disorder.

24 Jun 2014

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Forest Laboratories, Inc. today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD).

24 Jun 2014

TENS effective for poststroke urinary incontinence

Transcutaneous electrical nerve stimulation is effective for improving symptoms and enhancing quality of life in people who develop incontinence following a stroke, research suggests.

23 Jun 2014

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer in patients with wild-type epidermal growth-factor receptor tumour status.

23 Jun 2014

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.

23 Jun 2014

Denosumab increases bone density for postmenopausal women with osteoporosis

Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds.

23 Jun 2014

BPA appears to increase proliferation of breast cancer cells, diminish effectiveness of treatments

Bisphenol A (BPA), a chemical commonly used in plastics, appears to increase the proliferation of breast cancer cells, according to Duke Medicine researchers presenting at an annual meeting of endocrine scientists.

23 Jun 2014

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain.

23 Jun 2014

Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

Trevena, Inc. (NASDAQ:TRVN) today announced positive results from its Phase 1 trial of TRV734, which Trevena is developing with the goal of providing improved analgesia while avoiding gastrointestinal and respiratory side effects typically associated with opioids.

23 Jun 2014

NCL collaborates with PeptiMed to evaluate safety and efficacy of nanocomplex materials

PeptiMed announced today that under a Material Transfer Agreement it will collaborate with the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), located at the Frederick National Laboratory of Cancer Research in Frederick, MD.

23 Jun 2014

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

RegeneRx Biopharmaceuticals, Inc. and Lee's Pharmaceutical Holdings Ltd. today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China.

23 Jun 2014

Efficacy News and Research

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Mode of cancer cell recognition opens up new possibilities for leukaemia immunotherapy

Small antioxidant molecules suppress colon cancer associated with colitis

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

New study shows that bariatric patients face lower cancer risks

Trevena's Phase 1b data for TRV130 published in the journal Pain

SLU researchers discover pain pathway and potential way to block it

New invention provides simple, highly effective way for patients to self-treat keloid scars

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

TENS effective for poststroke urinary incontinence

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

Denosumab increases bone density for postmenopausal women with osteoporosis

BPA appears to increase proliferation of breast cancer cells, diminish effectiveness of treatments

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

NCL collaborates with PeptiMed to evaluate safety and efficacy of nanocomplex materials

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News